NEUROPATHOLOGY CORE

神经病理学核心的主要目标是促进和支持轻度认知障碍（MCI），阿尔茨海默病和其他神经退行性疾病的研究，通过银行和分布的良好特征的组织，再加上全面的神经病理学评估的ADC登记的情况下进行尸检。为了最好地实现这一目标，埃默里ADC将与印第安纳州大学ADC的神经病理学核心合作。这两个机构的综合资源及其独特的优势创造了一种协同关系，这种关系将在现有的机构间 通过以下活动，加强两个机构的合作，并支持实现神经病理学核心的主要目标：（1）对痴呆症患者、对照组和轻度认知障碍受试者的尸检大脑进行全面的神经病理学、生物化学和分子遗传学评估。该评估包括与其他神经系统疾病（例如，帕金森病和路易体痴呆、额颞叶痴呆和血管疾病）。(2)生成可靠的神经病理学数据，与临床核心收集的信息相关联，并用于埃默里大学的研究 大学、印第安纳州大学等院校。(3)维护一个活跃的组织库，以促进采集、储存、处理和分发特征良好的尸检脑组织、DMA和其他生物样本。(4)确定临床中心收集的所有血液样本和神经病理学中心收集的所有尸检病例的ApoE基因型，对与神经退行性疾病相关的其他基因进行分子遗传学分析，并使用 在基因分型过程中产生的DNA提取物、血浆样本和血沉棕黄层分离物的神经病理学核心库。

The primary goal of the Neuropathology Core is to promote and support research on mild cognitive impairment (MCI), Alzheimer's disease and other neurodegenerative disorders through banking and distribution of well-characterized tissue coupled with comprehensive neuropathologic assessment of ADC registry cases coming to autopsy. To best achieve this goal, the Emory ADC will work in partnership with the Neuropathology Core of the Indiana University ADC. The combined resources of the two institutions and their unique strengths create a synergistic relationship that will build upon already existing inter-institutional collaborations, enhance the capabilities of both institutions, and support the achievement of the primary goal of the Neuropathology Core through the following activities: (1) Comprehensive neuropathologic, biochemical and molecular genetic assessment of autopsy brains from dementia patients, controls and subjects with mild cognitive impairment. This assessment includes characterization of the heterogeneity of AD and dementias associated with other neurologic disorders (e.g., Parkinson's disease and Lewy body dementia, frontotemporal dementias, and vascular disease). (2) Generation of reliable neuropathologic data for correlation with information collected by the Clinical Core and for use in research studies at Emory University, Indiana University, and other institutions. (3) Maintenance of an active tissue bank to facilitate the acquisition, storage, handling, and distribution of well-characterized autopsy brain tissue, DMA, and other biological samples. (4) Determination of ApoE genotype on all blood samples accessioned by the Clinical Core and on all autopsy cases accessioned by the Neuropathology Core, molecular genetic analysis of other genes associated with neurodegenerative disease, and facilitation of collaborative investigations using the Neuropathology Core's bank of DNA extracts, plasma samples, and buffy coat isolates generated during the genotyping process.